<DOC>
	<DOCNO>NCT01156389</DOCNO>
	<brief_summary>Pyronaridine/ artesunate ( Pyramax ) antimalarial therapy demonstrate safe effective treatment patient Plasmodium falciparum vivax malaria . This drug interaction study intend investigate interaction Pyramax protease inhibitor ritonavir healthy subject use ritonavir probe substrate .</brief_summary>
	<brief_title>Pyronaridine/Artesunate -Ritonavir Drug Drug Interaction Study</brief_title>
	<detailed_description>This open label phase I , randomize , study determine drug interaction Pyramax ( pyronaridine/artesunate ) protease inhibitor ritonavir healthy volunteer . A total 34 healthy volunteer ( 17 per treatment arm ) enrol study least 30 ( 15 per treatment arm ) complete , randomly assign 1:1 ratio receive either ritonavir ( 100 mg bid ) 17 day Day 1-17 plus pyronaridine/artesunate ( 180:60 mg ) daily 3 day Day 8-10 arm A pyronaridine/artesunate ( 180:60 mg ) alone daily 3 day Day 1-3 arm B . Subjects come clinic even first dose Pyramax / ritonavir . If enrol , accord treatment arm subject stay clinic attend subsequent visit follow : Arm A : - Inpatient day -1 ( even ) day 17 - Ambulatory clinic visit daily ( morning ) day 22 , 29 , 36 , 43 50 ( end study visit ) Arm B : - Inpatient day -1 ( even ) day 4 ( morning ) , - Ambulatory clinic visit daily ( morning ) Day 5 , 6 , 8 , 15 , 22 , 29 , 36 , 43 . ( end study visit ) The subject evaluate pharmacokinetic parameter safety/tolerability .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Pyronaridine</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>1 . Male female subject age 18 55 year body weight 50 90 kg body mass index calculate use Quetelet 's Index weight ( kg ) /height2 ( m2 ) 18.530.0 2 . Signed date write informed consent form ( ICF ) undergo study related activity , include discontinuation prohibit medication 3 . Medically normal subject significant abnormal finding screen physical examination evaluate investigator 4 . Strictly normal value ALT , AST bilirubin normal abnormal clinically insignificant result ( agreed Investigator Sponsor case case evaluation ) blood urine laboratory parameter screen 5 . Female subject nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ( i.e. , one year without menses ) undergone sterilization ( via hysterectomy bilateral tubal ligation ) 6 . Female subject childbearing potential negative urine pregnancy test screen negative plasma pregnancy test prior inclusion agree one follow method : Double barrier method contraception 2 week first study drug administration throughout entire study follow period Partner ( ) undergo vasectomy negative sperm least 6 month 7 . The ability understand requirement study willingness comply study procedures 1 . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , acute QTc interval great equal 450 mseconds ) , respiratory ( include active tuberculosis ) , hepatic , renal , gastrointestinal , immunological ( include active HIVAIDS ) , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric clinical abnormality 2 . Known history hypersensitivity , allergic adverse reaction pyronaridine artesunate artemisinins ritonavir 3 . Known active Hepatitis A IgM ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) 4 . Seropositive HIV antibody 5 . Previous participation clinical study Pyramax 6 . Presence recent history ( last two year ) tobacco abuse ( â‰¥10 cigarettes/day ) 7 . Known suspected alcohol abuse illicit drug use last 10 year study start positive finding urine drug screen 8 . Intake grapefruit grapefruit juice alcoholic beverage caffeinecontaining food beverage , coffee , tea , chocolate , cola , 48 hour study drug administration 9 . Use overthecounter ( OTC ) medication , include vitamin , analgesic , antacid , 1 week study start 10 . Use prescription medication 14 day study start require chronic use prescription medication 11 . Use enzymealtering agent ( e.g. , barbiturate , phenothiazine , cimetidine , etc . ) within 30 day 5 half life , whichever longer , study start 12 . Plasma donation 1 month study start 13 . Blood donation 450 mL last 3 month study start 14 . Participation clinical study last 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>malaria</keyword>
	<keyword>artemisinin-based combination therapy</keyword>
</DOC>